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What nonhormonal
therapies are effective 
for postmenopausal
vasomotor symptoms?
■ EVIDENCE-BASED ANSWER
Regular exercise may reduce vasomotor symp-toms of menopause (strength of recommen-
dation [SOR]: C—single observational study).1
Soy products/isoflavones, either through diet
or supplementation, may reduce the incidence of
hot flushes (SOR: D—inconsistent results of 
randomized trials).2
Clonidine, as an oral or transdermal prepara-
tion, reduces hot flushes (SOR: A—randomized
clinical trials),3 as does gabapentin (SOR: A—
single randomized clinical trial).4
In cancer patients who have had surgical
menopause, selective serotonin reuptake inhib-
itors5 and megestrol6 (Megase) have been effective
in reducing hot flushes (SOR: A; B for extrapola-
tion to the general population).
Other therapies—including Bellergal (a combi-
nation of belladonna, ergotamine, and pheno-
barbital), methyldopa, evening primrose oil, mai
quan, flaxseed, ginseng, and topical wild yam
extract—have not been effective.7 Black cohosh
may be effective, but the evidence for this is of
poor quality (SOR: C). (See Table.)
Nonhormonal therapies for postmenopausal vasomotor symptoms
Agent Effective SOR† Comments
Soy/isoflavones Maybe D Multiple RCTs with conflicting results,
no formal meta-analysis. Does have
a positive effect on lipid profile
Clonidine (Catapres) Yes A Multiple small RCTs
Venlafaxine* (Effexor) Yes B Single RCT
Fluoxetine* (Prozac) Yes B Single RCT
Gabapentin (Neurontin) Yes A Single RCT
Megestrol* (Megace) Yes B Single RCT
Exercise Maybe C Single observational study
Black cohosh Maybe C German E commission recommenda
tion positive in 1989, but only 1 of 7 
trials cited had placebo control.
Recent RCT showed no benefit
Other: Bellergal, No C All have been advocated but no 
methyldopa, evening positive trials for any evidence 
primrose oil, ginseng, of effect
wild yam extract, mai 
quan, flaxseed
*Trials conducted only with patients with breast cancer and interventional menopause, most of whom were on anti-estrogen therapy.
†See page 290 for a description of strength of recommendation.
SOR, strength of recommendation; RCT, randomized controlled trial
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■ EVIDENCE SUMMARY
Hormone replacement therapy (HRT) is the stan-
dard treatment for vasomotor symptoms of
menopause, and it is effective for this indication.
With recent studies showing no benefit from long-
term HRT for menopausal women and increased
adverse effects with its use (especially for women
at risk for coronary heart disease), there has been
increased interest in nonhormonal treatments for
these symptoms. 
A small number of randomized clinical trials
have studied treatments other than HRT for the
control of vasomotor symptoms of menopause. As
a group, these trials have been short-term and
have involved small numbers of patients. A dis-
proportionate number of trials have been complet-
ed in breast cancer survivors, since these patients
tend to have more severe vasomotor symptoms as
a result of their anti-estrogenic therapies.
Whether these results can be generalized to all
postmenopausal women with vasomotor symp-
toms cannot be determined from the evidence. 
Eleven randomized trials of soy protein/
isoflavone used placebo controls. Results were
mixed, with 7 trials showing no effect and 4 show-
ing a reduction in hot flushes in comparison with
placebo. Studies reporting a positive effect
showed approximately a 15% reduction in
episodes in comparison with placebo. In one 
6-month trial, there was a correlation between hot
flushes and urinary isoflavone excretion regard-
less of treatment group, suggesting a confounding
effect of dietary intake of isoflavone. 
Five of six randomized controlled trials of cloni-
dine have shown a reduction in frequency of hot
flushes ranging from 14%–50% compared with
placebo. One trial, which used oral clonidine 0.1
mg daily, also reported an improved quality of life
for the treatment group. A single randomized trial
has shown that gabapentin, at a dose of 900
mg/day, is effective in reducing both frequency
and severity of hot flashes.4
Trials of specific selective serotonin reuptake
inhibitors have been completed in patients with
vasomotor symptoms secondary to breast cancer
therapies. Individual randomized controlled trials
of venlafaxine and fluoxetine have proven these
agents effective, and a preliminary open-labeled
trial of paroxetine has also suggested benefit. 
Several reviews suggest black cohosh may be
effective for short-term treatment, and it is used
in Germany for this indication. The trials we
found were not placebo-controlled, however, and
the safety of this agent is controversial. A single
English-language placebo-controlled trial did not
show any benefit for black cohosh.
■ RECOMMENDATIONS FROM OTHERS
The American College of Obstetrics and Gynec-
ology clinical management guideline, “The use of
botanicals for management of menopausal symp-
toms,” gives a level C recommendation (consensus
and expert opinion) that “Soy and isoflavone may
be helpful in short-term (≤2 years) treatment of
vasomotor symptoms” and “black cohosh may be
helpful in the short-term (≤6 months) treatment of
women with vasomotor symptoms.” They note
that “given the possibility that these compounds
may interact with estrogen, these agents should
not be considered free of potential harm in women
with estrogen-dependent cancers.”8
The North American Menopause Society notes
that behavior changes, such as moderate exercise
and avoidance of hot-flush triggers, may prevent
some hot flushes, although there is only anecdot-
al evidence for this. The efficacy of paced respira-
tion—deep, slow abdominal breathing—to lessen
hot flushes has been shown in a small trial. The
society states that other alternative therapies
have not been shown to be efficacious, except for
moderate quantities of soy products.9
The Medical Letter says the evidence that phy-
toestrogens are helpful for menopausal women
comes mostly from epidemiological studies. The
long-term adverse effects of phytoestrogen 
consumption are not known.10
Dan Brewer, MD, Department of Family Medicine,
University of Tennessee–Knoxville; Joan Nashelsky,
MLS, Family Practice Inquiries Network, East 
Lansing, Mich
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■ CLINICAL COMMENTARY
Behavioral modifications may be the first
approach to reduce the incidence of vasomotor
symptoms in menopausal women. Recom-
mendations include wearing several layers 
of breathable clothing; keeping a glass of 
cold water, ice pack, or small fan by the bedside
and nearby at work; performing deep breathing
relaxation techniques; and exercising routinely. 
Effective nonhormonal treatments include
phytoestrogens (≤2 years), black cohosh (≤6
months), clonidine, selective serotonin reup-
take inhibitors, and venlafaxine. Overall, there
are few well-designed clinical trials regarding
the safety and effectiveness of botanical agents
used for vasomotor symptoms. Since the Food
and Drug Administration does not regulate the
marketing and standardization of these prod-
ucts, patients should be advised to purchase
products from reputable companies with inter-
nal standardization processes. 
Additionally, patients should talk with their
health care provider prior to initiating any
alternative medication to avoid drug-disease
and drug-drug interactions.
Laura B. Hansen, PharmD, BCPS, University of
Colorado Health Sciences Center, Denver
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What treatments are effective
for varicose veins?
■ EVIDENCE-BASED ANSWER
For larger trunk varicose veins, as in thesaphenous vein, therapeutic options include
conservative measures (such as leg elevation
and compression stockings), injection sclero-
therapy, and surgical vein ligation, with or
without stripping. Long-term outcomes appear
superior with surgical treatment. 
For mid-sized reticular veins and spider
telangiectasias, several options are available,
including sclerotherapy, laser ablation, and
thermal ablation. However, no randomized trials
have compared the relative effectiveness of
these treatments.
Venotonic medications (primarily plant-
derived and synthetic flavonoids, such as horse
chestnut seed extract, that improve venous
tone) provide symptom relief. Head-to-head
comparisons are needed to identify the most
efficacious therapies (strength of recom-
mendation: C, based on case series and
extrapolations from small trials.)
■ EVIDENCE SUMMARY
Graduated elastic compression stockings
improve lower-extremity hemodynamics (includ-
ing reflux and residual volume measured by
color flow duplex scanning) in patients with
varicosities, and can improve symptoms such as
swelling, discomfort, and leg tightness.1,2
A Cochrane review concluded that existing
evidence supports the use of sclerotherapy 
for recurrent varicose veins after surgery and
